Logo 1-1.png
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
19 nov. 2024 07h00 HE | Chemomab Therapeutics
Oral presentation at AASLD highlights broad clinical activity of Chemomab’s CM-101 across multiple biomarkers and its disease-modifying potential in PSC
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
28 nov. 2023 08h00 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Harpoon_logo (002).jpg
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
02 nov. 2023 09h15 HE | Harpoon Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Florida Cancer Specialists & Research Institute is well represented at the 2022 ASCO Annual Meeting.
Florida Cancer Specialists & Research Institute Presents Clinical Research Results at 2022 ASCO® Annual Meeting
03 juin 2022 09h57 HE | Florida Cancer Specialists & Research Institute
Fort Myers, Florida, June 03, 2022 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute, LLS (FCS) physicians are presenting the outcomes of 33 clinical trials, the majority being...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
02 mai 2022 16h45 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
New Logo.png
Provectus Biopharmaceuticals Announces Oral Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda® for Checkpoint-Refractory Advanced Cutaneous Melanoma at Melanoma Bridge 2020
07 déc. 2020 07h00 HE | Provectus Biopharmaceuticals Inc.
29% ORR (7% CR) and 57% DCR (RECIST 1.1)75% ORR in anti-PD-1-refractory patients56% DCR (11% CR) in patients refractory to anti-CTLA-4 and anti-PD-1 combination therapyPresentation delivered by...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting
30 nov. 2020 07h05 HE | uniQure Inc.
~ Strong Presence at ASH Featuring Five Presentations, Including Late-BreakingOral Presentation on HOPE-B Pivotal Trial ~ ~ uniQure to Host Investor Webcast Tuesday, December 8, 2020 at 5:00 p.m. ET...
provectus_logo.jpg
Provectus Biopharmaceuticals Announces Acceptance of PV-10® Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020
12 nov. 2020 08h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing Phase 1b/2 study of autolytic cancer immunotherapy PV-10, an injectable...
logo.jpg
Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020
26 août 2020 18h05 HE | Genmab A/S
Media Release Copenhagen, Denmark, Aug 27, 2020 InnovaTV 204 study evaluated tisotumab vedotin in recurrent or metastatic cervical cancer Data from the study selected as a late-breaking abstract at...
Achillion-Logo-150 (4).jpg
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
05 déc. 2015 17h00 HE | Achillion Pharmaceuticals, Inc.
- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal...